COMP <GO>
SLS vs SRPT // EV/EBITDA & P/E VALUATION
SELLAS Life Sciences Group Inc. (NASDAQ) VS. Sarepta Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SLS 3
— SRPT 2
■ METRIC PARITY
LAST: $10.15 (-2.17%) • MKT CAP: $2.05B
valuation
—
LAST: $19.23 (-0.47%) • MKT CAP: $2.03B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLS VS. SRPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SLS | SRPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.80% | -35.00% | +13.20 | SLS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | -15.14% | +13.76 | SLS | /fcf-yield <GO> |
| Operating Margin | — | -37.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -38.30% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 4.30% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | SRPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.7 | 51.2 | -12.55 | SRPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.05B | $2.03B | $19.6M | SLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SLS REV | SRPT REV | SLS GROSS % | SRPT GROSS % | SLS FCF | SRPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.86B | — | 98.0% | -$28.4M | -$307.5M |
| FY 2024 | $0 | $1.79B | — | — | -$35.4M | -$342.7M |
| FY 2023 | $0 | $1.14B | — | — | -$31.4M | -$501.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLS // BETA —
SRPT // BETA —